0
Signin
countryflagUS

18889881171

AAPL 174.545 3.0981% MSFT 400.8 -1.3585% GOOG 168.575 -2.9449% GOOGL 166.78 -3.0067% AMZN 180.55 0.5178% NVDA 872.0 -0.6098% META 432.1 -2.5243% TSLA 193.965 15.2564% TSM 137.52 -0.564% LLY 735.26 0.2386% V 272.48 -0.7431% AVGO 1336.05 -0.5967% JPM 193.42 -0.0362% UNH 490.57 -0.965% NVO 127.045 0.1537% WMT 60.075 -0.1413% LVMUY 167.187 -1.2422% XOM 119.54 1.3394% LVMHF 834.7 -1.2014% MA 457.31 -1.1051%

Unity Biotechnology Inc

Healthcare US UBX

1.515USD
0.01(1.00%)

Last update at 2024-04-29T17:24:00Z

Day Range

1.501.52
LowHigh

52 Week Range

1.465.72
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -59.92700M -60.72500M -93.84400M -82.17700M -76.39800M
Minority interest - - - - -
Net income -57.74700M -60.03900M -91.86900M -74.87300M -76.39800M
Selling general administrative 20.95M 23.06M 24.02M 20.05M 16.02M
Selling and marketing expenses - - - - -
Gross profit 0.24M 4.78M - -70.95700M -58.90700M
Reconciled depreciation 2.18M 2.88M 3.45M 2.66M 2.18M
Ebit -57.57200M -56.66500M -93.93000M -89.65100M -72.56100M
Ebitda -56.36900M -57.54800M -89.95600M -92.35500M -70.38100M
Depreciation and amortization 1.20M -0.88300M 3.97M -2.70400M 2.18M
Non operating income net other -0.22400M - 0.18M 4.18M -0.24500M
Operating income -57.57200M -56.66500M -93.93000M -89.65100M -79.46500M
Other operating expenses 57.81M 61.45M 91.33M 91.00M 74.92M
Interest expense 3.56M 3.18M 1.29M 0.00000M 3.31M
Tax provision - - - - -
Interest income 1.22M 0.10M 1.20M 3.29M 3.31M
Net interest income -2.33800M -3.07700M -0.09600M 3.29M 3.31M
Extraordinary items - - - - -
Non recurring - - 2.63M - -
Other items - - - - -
Income tax expense -2.18000M -0.68600M -1.97500M -7.30400M 3.07M
Total revenue 0.24M 4.78M 0.00000M 0.00000M 0.00000M
Total operating expenses 57.81M 61.45M 91.33M 91.00M 74.92M
Cost of revenue - - - 70.96M 58.91M
Total other income expense net -2.35500M -4.06000M 0.09M 7.47M -4.78700M
Discontinued operations - - - - -
Net income from continuing ops -60.13400M -60.72500M -93.84400M -82.17700M -76.39800M
Net income applicable to common shares -59.92700M -60.72500M -93.84400M -82.17700M -76.39800M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 124.35M 124.71M 156.32M 151.22M 181.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.74M 1.88M 3.17M 2.00M 1.83M
Total liab 57.50M 65.14M 73.44M 30.51M 20.68M
Total stockholder equity 66.85M 59.57M 82.88M 120.71M 160.69M
Deferred long term liab - - - 13.30M 2.47M
Other current liab 8.35M 11.36M 0.02M 12.03M 11.73M
Common stock 0.00100M 0.00600M 0.00500M 0.00500M 0.00400M
Capital stock 0.00100M 0.00600M 0.00500M 0.00500M 0.00400M
Retained earnings -459.95100M -400.02400M -339.29900M -245.45500M -163.27800M
Other liab - 0.02M - 13.30M 4.05M
Good will - - - - -
Other assets 0.95M 0.99M 1.45M 2.07M 1.17M
Cash 12.74M 32.91M 17.81M 37.47M 15.40M
Cash and equivalents - - - - -
Total current liabilities 19.62M 16.62M 14.46M 17.22M 16.58M
Current deferred revenue - 0.22M 7.36M - -
Net debt 34.62M 18.65M 41.17M -37.47300M -15.27500M
Short term debt 9.48M 3.06M 4.52M - -
Short long term debt 9.48M 3.06M - - -
Short long term debt total 47.36M 51.56M 58.98M 0.04M 0.12M
Other stockholder equity 527.05M 459.63M 422.17M 366.07M 142.69M
Property plant equipment 7.83M 31.23M 36.14M 16.64M 6.24M
Total current assets 96.53M 90.50M 100.87M 129.49M 172.97M
Long term investments 0.00000M 1.99M 17.87M 3.02M 0.00000M
Net tangible assets 66.85M 59.57M 82.88M 120.71M 160.69M
Short term investments 82.06M 55.17M 79.89M 90.02M 155.74M
Net receivables - - - - -
Long term debt 10.89M 18.41M 24.51M - -
Inventory - - - - -
Accounts payable 1.79M 1.99M 2.56M 5.18M 4.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.25100M -0.04400M 0.00500M 0.09M -0.09500M
Additional paid in capital - - - - -
Common stock total equity 0.00100M - 0.00500M 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity -459.95100M - -339.29900M -245.45500M -163.27800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.95M 0.99M 1.45M 2.07M 2.17M
Deferred long term asset charges - - - - -
Non current assets total 27.82M 34.21M 55.45M 21.73M 8.41M
Capital lease obligations 30.09M 34.47M 38.99M - -
Long term debt total 10.89M - 24.51M - 0.05M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -24.82700M 39.51M -5.20800M 69.54M -70.94200M
Change to liabilities -1.19900M -0.35700M -2.64000M 1.30M 5.28M
Total cashflows from investing activities -24.54500M 39.31M -5.20800M 67.95M -72.20600M
Net borrowings - -0.06800M 24.50M -0.07300M 0.82M
Total cash from financing activities 54.85M 20.84M 63.88M 27.44M 136.93M
Change to operating activities -0.82800M -0.27400M -1.91400M 3.79M 1.52M
Net income -59.92700M -60.72500M -93.84400M -82.17700M -76.39800M
Change in cash -20.71900M 15.10M -19.66600M 22.97M 8.10M
Begin period cash flow 34.35M 19.25M 38.92M 15.95M 7.85M
End period cash flow 13.63M 34.35M 19.25M 38.92M 15.95M
Total cash from operating activities -51.02900M -45.06000M -78.33300M -72.42100M -56.62300M
Issuance of capital stock 54.71M 18.57M 37.27M 26.09M 138.94M
Depreciation 2.18M 2.88M 3.45M 2.66M 2.18M
Other cashflows from investing activities 0.38M - 6.01M 69.54M -70.94200M
Dividends paid - - - -0.02700M 60.75M
Change to inventory - - - - -
Change to account receivables - - - - 1.38M
Sale purchase of stock 54.85M - 1.51M 0.03M 0.40M
Other cashflows from financing activities 0.15M 2.34M 27.01M 1.43M 118.30M
Change to netincome 8.83M 12.60M 16.30M 10.85M 9.44M
Capital expenditures 0.10M 0.20M 0.65M 1.59M 1.26M
Change receivables - - - - -
Cash flows other operating -1.95900M - -0.90700M -3.90800M 3.83M
Exchange rate changes - - - - -
Cash and cash equivalents changes -20.71900M - -19.66600M 22.97M 8.10M
Change in working capital -1.02200M -0.63100M -4.55400M 3.56M 5.13M
Stock based compensation 9.38M 11.55M 13.81M 10.85M 9.44M
Other non cash items -1.63900M 0.94M 0.42M -0.38700M 4.54M
Free cash flow -51.12500M -45.25500M -78.97900M -74.00700M -57.88700M

Fundamentals

  • Previous Close 1.50
  • Market Cap26.86M
  • Volume28645
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-43.50400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -35.22300M
  • Diluted EPS TTM-3.2

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
UBX
Unity Biotechnology Inc		 0.01 1.00% 1.51 - - 7.89 0.77 29.79 -0.1331
NVO
Novo Nordisk A/S		 0.20 0.15% 127.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.36 1.09% 126.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.5 0.13% 396.98 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.25 1.40% 90.85 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology Inc

285 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Anirvan Ghosh Ph.D. CEO & Director 1964
Dr. Nathaniel E. David A.B., Ph.D. Co-Founder & Exec. Director 1968
Ms. Lynne Marie Sullivan CFO & Head of Corp. Devel. 1967
Dr. Jamie Dananberg M.D. Chief Medical Officer 1958
Dr. Jan M. van Deursen Founder NA
Dr. Judith Campisi Ph.D. Founder NA
Mr. Daohong Zhou M.D. Founder NA
Mr. Nathan Guz Ph.D. VP of Operations NA
Mr. Alexander Azoy VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer 1976
Dr. Przemyslaw Sapieha Ph.D. Chief Scientific Advisor NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).